India Pharma Outlook Team | Thursday, 05 November 2026
Brazil’s semaglutide market is gaining momentum as Dr. Reddy's Laboratories receives marketing authorization from Brazil's health agency ANVISA for its semaglutide injection.
The approval allows the Indian pharmaceutical company to expand its presence in one of Latin America's significant diabetes treatment markets.
Dr. Reddy's plans to commercialize the product in partnership with Brazilian pharmaceutical company Ache.
With the country's diabetes semaglutide market estimated at USD 244.6 million, the development presents a commercial opportunity.
However, the company is entering a market where domestic manufacturers and other pharmaceutical players are already strengthening their positions in the expanding GLP-1 drug market.
Brazil represents a substantial opportunity for pharmaceutical companies targeting diabetes treatment. According to Dr. Reddy's, approximately 16.6 million adults in the country are living with diabetes.
The company estimates Brazil's semaglutide market for diabetes treatment at approximately USD 244.6 million.
The competitive landscape has evolved following the expiry of semaglutide's patent in Brazil in March 2026. This opened opportunities for pharmaceutical manufacturers to introduce alternative products, subject to regulatory approval.
In May 2026, ANVISA approved Ozivy, developed by Brazilian pharmaceutical company EMS, as the country's first synthetic semaglutide analogue for diabetes treatment.
These developments have increased competition and created additional treatment options for patients with type 2 diabetes. Brazil’s semaglutide market is therefore moving beyond the initial entry of alternative products towards a more competitive environment.
Also Read: AI in Pharma Quality: Opportunities and Compliance Challenges
Dr. Reddy's will enter the market with a pre-filled, multi-dose injectable pen available in two presentations: 2 mg/1.5 mL and 4 mg/3 mL.
The product is indicated for adults with insufficiently controlled type 2 diabetes mellitus, alongside diet and exercise. It can be used when metformin is unsuitable or in combination with other diabetes medicines.
The company will commercialize the product through its partnership with Aché, which provides a local market presence and commercial distribution capabilities.
MV Ramana, Chief Executive Officer of Global Generics at Dr. Reddy's Laboratories, highlighted Brazil's diabetes burden and the commercial significance of the market.
He indicated that the approval supports the company's objective of expanding access to semaglutide treatment options across international markets.
Semaglutide has emerged as an important opportunity for Indian pharmaceutical companies as patent expiries create possibilities for alternative products in international markets.
Brazil's experience also demonstrates that regulatory approval alone does not guarantee commercial success. Manufacturers must establish consistent product quality, reliable supply chains, competitive pricing and local distribution networks.
For Indian pharmaceutical exports, the development highlights the potential of Latin American markets as destinations for complex pharmaceutical formulations.
Brazil’s semaglutide market could provide Dr. Reddy's with an opportunity to strengthen its international generics business while expanding its presence in diabetes treatment.
.jpg)
